...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
【24h】

Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia

机译：长效可注射帕潘立酮棕榈酸酯对精神分裂症患者的症状域起效和持续疗效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Several long-acting injectable (LAI) second-generation antipsychotics are now available for the management of schizophrenia. As patients with schizophrenia frequently present with diverse and challenging symptoms, it is important to understand the effects of antipsychotics in treating these different symptom subgroups and the timing of these responses. Areas covered: For this review, data from two randomized, double-blind trials were analyzed in respect to the onset and persistence of effects on several measures of psychopathology (as measured by the Positive and Negative Syndrome Scale [PANSS]) after treatment with LAI paliperidone palmitate (PP) (NCT00590577 and NCT00589914). Expert opinion: Symptom reductions from baseline with PP were significant by day 4 for all five PANSS factors in both studies. Some effects may have been driven by the presence or absence of a placebo response. A significant effect for PP versus placebo was observed for all major symptom domains for one or more doses of PP during the first month of treatment. Once established, most (but not all) significant responses persisted to the end point. Similar improvements were observed in PANSS scores with PP and oral risperidone. Dose-dependent trends were observed for the effect of PP on positive, negative and uncontrolled hostility/excitement symptoms.
机译：简介：几种长效可注射（LAI）第二代抗精神病药现已可用于精神分裂症的治疗。由于精神分裂症患者经常表现出多样且具有挑战性的症状，因此重要的是要了解抗精神病药在治疗这些不同症状亚组中的作用以及这些反应的时机。涵盖的领域：对于本评价，分析了两项随机，双盲试验的数据，分析了LAI治疗后对几种心理病理学指标（以阳性和阴性综合征量表[PANSS]衡量）的影响的发作和持续性。帕潘立酮棕榈酸酯（PP）（NCT00590577和NCT00589914）。专家意见：在两项研究中，对于所有五个PANSS因子，PP的症状自第4天起均显着降低。某些作用可能是由是否存在安慰剂反应引起的。在治疗的第一个月中，对于一剂或多剂剂量的PP，在所有主要症状域中均观察到PP与安慰剂的显着效果。一旦建立起来，大多数（但不是全部）重要的回应就会持续到终点。 PP和口服利培酮对PANSS评分也有类似的改善。观察到PP对阳性，阴性和不受控制的敌意/兴奋症状的作用呈剂量依赖性趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号